Drug Profile
Endothelial stem cell therapy - Regen BioPharma
Alternative Names: Aplastic anemia stem cell therapy - Regen BioPharma; Autologous stromal vascular fraction cells - Regen BioPharma; HemaXellerate I™; HemaXellerate™Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Regen BioPharma
- Developer Cascade LifeSciences; Pan American Cancer Treatment Center; Regen BioPharma
- Class Stem cell therapies
- Mechanism of Action Bone marrow cell stimulants; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Aplastic anaemia; Myelosuppression
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Myelosuppression in Mexico (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Aplastic-anaemia in USA (Parenteral)
- 29 Jan 2019 Endothelial stem cell therapy is still in Preclinical phase for Aplastic anaemia in USA (Regen BioPharma pipeline, January 2019)